The controversy surrounding indomethacin for tocolysis

George A. Macones, Sara Joy Marder, Bonnie Clothier, David M. Stamilio

Research output: Contribution to journalArticle

52 Scopus citations

Abstract

Indomethacin is a prostaglandin synthetase inhibitor sometimes used for tocolysis. Several placebo-controlled trials and trials comparing indomethacin to other potential first-line tocolytic agents support its efficacy for delaying delivery for >48 hours. Recent observational studies, however, have raised concerns about the safety of indomethacin, implicating it with increased rates of intraventricular hemorrhage and necrotizing enterocolitis. Careful analysis of these observational studies suggests that these results should be viewed with caution, because of uncontrolled confounding by indication. A recent decision analysis supports the risk/benefit analysis of indomethacin in this setting. Still, the future of indomethacin in preterm labor should be guided by well-designed prospective clinical trials. Such studies are underway.

Original languageEnglish
Pages (from-to)264-272
Number of pages9
JournalAmerican journal of obstetrics and gynecology
Volume184
Issue number3
DOIs
StatePublished - Jan 1 2001

Keywords

  • Indomethacin
  • NSAID
  • Tocolysis

Fingerprint Dive into the research topics of 'The controversy surrounding indomethacin for tocolysis'. Together they form a unique fingerprint.

  • Cite this

    Macones, G. A., Marder, S. J., Clothier, B., & Stamilio, D. M. (2001). The controversy surrounding indomethacin for tocolysis. American journal of obstetrics and gynecology, 184(3), 264-272. https://doi.org/10.1067/mob.2001.111718